Optimizing immunoglobulin G dosing for obese patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how obesity affects the pharmacokinetics of immunoglobulin G (IgG) and aims to develop optimal dosing strategies for IgG in obese patients. It addresses the lack of consensus on dosing methods, such as total body weight versus ideal or adjusted body weight, which may impact treatment efficacy and safety. The study will analyze the clinical implications of different dosing strategies to minimize adverse reactions and improve outcomes for patients receiving intravenous immune globulin treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* aged 18 to 75 years
* currently treated with IVIG

Exclusion Criteria:

* liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal)
* reduced renal function (CrCl \< 50 mL/min)
* Patients with a pacemaker or an automatic implantable cardioverter-defibrillator

Where it's running

• Robert Wood Johnson University Hospital Somerset
  Somerville, New Jersey, United States Recruiting

Study contacts

• Principal investigator: Luigi Brunetti, Ph D; PharmD — Rutgers University
• Study coordinator: Luigi Brunetti, Ph D; PharmD
• Email: luigi.brunetti@rutgers.edu
• Phone: 7324455215

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.